Skip to main content


Fig. 5 | Alzheimer's Research & Therapy

Fig. 5

From: FUNDAMANT: an interventional 72-week phase 1 follow-up study of AADvac1, an active immunotherapy against tau protein pathology in Alzheimer’s disease

Fig. 5

Sera of patients treated with AADvac1 recognise tau pathology in progressive supranuclear palsy (PSP) and corticobasal degeneration (CBD). ad PSP. gl CBD. Sera of three different patients with different strengths of antibody response (patient R17 with an anti-AD-tau titre of 1:30,999; patient R25 with 1:18,185; and patient R10 with 1:12,800) were used for staining. Staining with pre-treatment sera is shown as a negative control (df, jl)

Back to article page